D S Tsang1, L Khan1, J R Perry2, H Soliman1, A Sahgal1, J L Keith3, T G Mainprize4, S Das5, L Zhang6, M N Tsao7. 1. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. 2. Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. 3. Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. 4. Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. 5. Division of Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, Canada. 6. MacroStat. Inc., Toronto, Canada. 7. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. Electronic address: may.tsao@sunnybrook.ca.
Abstract
AIMS: Many elderly glioblastoma patients are excluded from randomised trials due to age, comorbidity or poor functional status. The purpose of this study was to describe the survival outcomes in all elderly patients with glioblastoma managed at a tertiary cancer centre. MATERIALS AND METHODS: A retrospective chart review identified 235 elderly patients (age 65 years or over) with a histological diagnosis of glioblastoma between 1 December 2006 and 31 December 2013. The primary outcome of this study was overall survival by treatment type. Univariate and multivariate Cox proportional hazard models were used to explore significant prognostic variables associated with overall survival. RESULTS: The median survival for all patients was 6.5 months (95% confidence interval 5.3-7.7), with 1 year overall survival of 23.7% (95% confidence interval 18.8-30.0). The median survival for patients treated with radiation and chemotherapy was 11.1 months (95% confidence interval 8.1-13.7). Patients treated with radiation alone had a median survival of 6.8 months (95% confidence interval 5.6-7.9). For patients managed with comfort measures only, the median survival was 1.9 months (95% confidence interval 1.6-2.6). Univariate analysis revealed age, performance status, surgery type (biopsy, subtotal resection, gross total resection) and type of treatment received (comfort measures only, radiotherapy alone, radiotherapy and chemotherapy) to be statistically associated with overall survival. In the multivariate analysis, only two predictive factors (treatment received and surgery type) were significant. CONCLUSIONS: Elderly patients with glioblastoma selected for treatment (surgery followed by radiation alone or radiation and chemotherapy) survive longer than patients managed with comfort measures. Prospective randomised trials will help guide management for patients eligible for therapy. Elderly patients with glioblastoma who are deemed not eligible for active therapy have very short survival.
AIMS: Many elderly glioblastomapatients are excluded from randomised trials due to age, comorbidity or poor functional status. The purpose of this study was to describe the survival outcomes in all elderly patients with glioblastoma managed at a tertiary cancer centre. MATERIALS AND METHODS: A retrospective chart review identified 235 elderly patients (age 65 years or over) with a histological diagnosis of glioblastoma between 1 December 2006 and 31 December 2013. The primary outcome of this study was overall survival by treatment type. Univariate and multivariate Cox proportional hazard models were used to explore significant prognostic variables associated with overall survival. RESULTS: The median survival for all patients was 6.5 months (95% confidence interval 5.3-7.7), with 1 year overall survival of 23.7% (95% confidence interval 18.8-30.0). The median survival for patients treated with radiation and chemotherapy was 11.1 months (95% confidence interval 8.1-13.7). Patients treated with radiation alone had a median survival of 6.8 months (95% confidence interval 5.6-7.9). For patients managed with comfort measures only, the median survival was 1.9 months (95% confidence interval 1.6-2.6). Univariate analysis revealed age, performance status, surgery type (biopsy, subtotal resection, gross total resection) and type of treatment received (comfort measures only, radiotherapy alone, radiotherapy and chemotherapy) to be statistically associated with overall survival. In the multivariate analysis, only two predictive factors (treatment received and surgery type) were significant. CONCLUSIONS: Elderly patients with glioblastoma selected for treatment (surgery followed by radiation alone or radiation and chemotherapy) survive longer than patients managed with comfort measures. Prospective randomised trials will help guide management for patients eligible for therapy. Elderly patients with glioblastoma who are deemed not eligible for active therapy have very short survival.
Authors: Dieter Henrik Heiland; Gerrit Haaker; Ralf Watzlawick; Daniel Delev; Waseem Masalha; Pamela Franco; Marcia Machein; Ori Staszewski; Oliver Oelhke; Nils Henrik Nicolay; Oliver Schnell Journal: J Neurooncol Date: 2018-08-03 Impact factor: 4.130
Authors: Ali S Arbab; Mohammad H Rashid; Kartik Angara; Thaiz F Borin; Ping-Chang Lin; Meenu Jain; Bhagelu R Achyut Journal: Int J Mol Sci Date: 2017-12-16 Impact factor: 5.923
Authors: Mirjam Renovanz; Anne-Katrin Hickmann; Minou Nadji-Ohl; Naureen Keric; Elke Weimann; Christian Rainer Wirtz; Susanne Singer; Florian Ringel; Jan Coburger Journal: Support Care Cancer Date: 2020-02-14 Impact factor: 3.603